This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CSCI COSCIENS Biopharma (CSCI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisEarningsHeadlinesTrendsBuy This Stock About COSCIENS Biopharma Stock (NASDAQ:CSCI) Get COSCIENS Biopharma alerts:Sign Up Key Stats Today's Range$2.72▼$2.7250-Day Range$2.61▼$3.9552-Week Range$2.50▼$4.40VolumeN/AAverage Volume7,571 shsMarket Capitalization$8.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. Read More Receive CSCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COSCIENS Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CSCI Stock News HeadlinesCOSCIENS Biopharma Inc. Completes Share Capital AmendmentJuly 3 at 8:51 AM | financialpost.comFCOSCIENS Biopharma Sets July 3 Effective Date for Share Capital Overhaul and U.S. Reporting ExitJune 23, 2026 | tipranks.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.July 5 at 1:00 AM | Porter & Company (Ad)COSCIENS Biopharma Inc. Announces Details of Share Capital AmendmentJune 22, 2026 | financialpost.comFCOSCIENS Biopharma Inc. Announces Details of Share Capital AmendmentJune 22, 2026 | markets.businessinsider.comCOSCIENS Biopharma Inc. Announces Details of Share Capital AmendmentJune 22, 2026 | globenewswire.comCOSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEOJune 18, 2026 | financialpost.comFCOSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEOJune 18, 2026 | globenewswire.comSee More Headlines CSCI Stock Analysis - Frequently Asked Questions How were COSCIENS Biopharma's earnings last quarter? COSCIENS Biopharma Inc. (NASDAQ:CSCI) released its quarterly earnings data on Thursday, August, 14th. The company reported ($0.85) earnings per share (EPS) for the quarter. The company had revenue of $2.75 million for the quarter. COSCIENS Biopharma had a negative trailing twelve-month return on equity of 149.49% and a negative net margin of 199.55%. What other stocks do shareholders of COSCIENS Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that COSCIENS Biopharma investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), Baidu (BIDU). Company Calendar Last Earnings8/14/2025Today7/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CSCI CIK1113423 Webwww.cosciensbio.com Phone49-6942-6020Fax418-948-9191Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($6.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.31 million Net Margins-199.55% Pretax Margin-189.27% Return on Equity-149.49% Return on Assets-54.80% Debt Debt-to-Equity RatioN/A Current Ratio2.98 Quick Ratio2.65 Sales & Book Value Annual Sales$9.44 million Price / Sales0.91 Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.78Miscellaneous Outstanding Shares3,176,000Free Float3,173,000Market Cap$8.64 million OptionableN/A Beta0.91 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CSCI) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
